News | February 28, 2023
ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
Ayurveda is one of the most advanced sciences of its times
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
There is a fast resurgence in the transplant activities post COVID
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
Subscribe To Our Newsletter & Stay Updated
